Evidence map›Paper›PMID 30171223›Full record

ArticleBone marrow transplantation2019

Associations between febrile neutropenia-related parameters and the risk of acute GVHD or non-relapse mortality after allogeneic hematopoietic stem cell transplantation.

Kazuaki Kameda, Shun-Ichi Kimura, Yukiko Misaki, Kazuki Yoshimura, Ayumi Gomyo, Jin Hayakawa, Masaharu Tamaki, Machiko Kusuda, Yu Akahoshi, Tomotaka Ugai and 11 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Kazuaki KamedaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Shun-Ichi KimuraDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Yukiko MisakiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Kazuki YoshimuraDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Ayumi GomyoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Jin HayakawaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.ORCID http://orcid.org/0000-0003-3931-1730
Masaharu TamakiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Machiko KusudaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Yu AkahoshiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.ORCID http://orcid.org/0000-0001-6825-9340
Tomotaka UgaiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Yuko IshiharaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Koji KawamuraDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Kana SakamotoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Aki TaniharaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Hidenori WadaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Miki SatoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Kiriko Terasako-SaitoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Misato KikuchiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Hideki NakasoneDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Shinichi KakoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Yoshinobu KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan. ycanda-tky@umin.ac.jp.
Jichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infection and inflammation can induce acute graft-vs.-host disease (aGVHD). We hypothesized that febrile neutropenia early after allogeneic hematopoietic cell transplantation (HCT) would increase the risk of aGVHD and non-relapse mortality (NRM). We retrospectively evaluated the impact of fever, C-reactive protein (CRP) concentration and blood stream infection (BSI) early after HCT on the incidence of grade II-IV aGVHD and NRM in 227 patients. Within 7 days after HCT, 91 (40.1%) patients experienced fever for at least 2 days (early-FN group). BSI occurred in 27 (11.9%) patients and the maximum CRP concentration was 2.57 mg/dl in the median. In a multivariate analysis, early-FN (hazard ratio (HR) 1.81, P = 0.007) and older recipient age (HR 1.68, P = 0.019) were significantly associated with the incidence of grade II-IV aGVHD. High-CRP and BSI were not significant risk factors for grade II-IV aGVHD. On the other hand, high-CRP was significantly associated with the incidence of NRM (HR 2.67, P = 0.004) in a multivariate analysis. In conclusion, although fever, CRP elevation and BSI are considered to be closely related events, they had different effects on the incidence of aGVHD and NRM. The development of early-FN after HCT may predict the risk of aGVHD.

Indexed as

Febrile NeutropeniaGraft vs Host DiseaseHematopoietic Stem Cell TransplantationInfectionsAcute DiseaseAdolescentAdultAgedAge FactorsAllograftsC-Reactive ProteinDisease-Free SurvivalFemaleHumansMaleMiddle AgedC-Reactive Protein

Identifiers

PMID30171223
OpenAlexW2889516274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.